Compounding Pharmacy Recalls Injectable Medication Vials for Manufacturing Quality Failures
Olympia Compounding Pharmacy recalls 1,871 multi-dose vials of QM-2 injectable medication due to failure to properly investigate manufacturing monitoring excursions prior to October 2021. No illnesses reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a Class II recall involving CGMP violations at a compounding facility where monitoring excursions were not properly investigated, constituting a risk-of-harm product. No illnesses or injuries have been reported, keeping the score at the maximum permitted for recalls with theoretical hazard and no confirmed injury.
Plain-English summary
Olympia Compounding Pharmacy is recalling approximately 1,871 multi-dose vials of QM-2 injectable medication (containing Papaverine, Phentolamine, Alprostadil, and Atropine) distributed nationwide in the United States.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) compliance violations. Specifically, prior to October 1, 2021, the facility failed to properly investigate environmental and personnel monitoring excursions that exceeded acceptable limits.
The affected lot codes are D41219 (Best Use Date: April 19, 2022) and I24C13 (Best Use Date: September 13, 2022). No illnesses or injuries have been reported in connection with this recall.
The recalled product
- Product
- QM-2 Papaverine 30 mg/mL. Phentolamine 3 mg/mL . Alprostadil 60 mcg/mL . Atropine 0.2 mg/mL, Multi-Dose 10 mL vial, Rx Only Olympia Pharmaceuticals 6700 Convoy Rd., Ste. 155, Orlando, FL 32835. NDC: 73198-0018-10.
- Manufacturer
- Olympia Compounding Pharmacy dba Olympia Pharmacy
- Category
- Drug — Injectable
- Hazard
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lots: D41219 BUD: 4/19/2022
- I24C13 BUD: 9/13/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27